X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6146) 6146
Publication (857) 857
Book / eBook (149) 149
Book Chapter (103) 103
Book Review (89) 89
Newsletter (50) 50
Conference Proceeding (24) 24
Magazine Article (7) 7
Dissertation (3) 3
Reference (3) 3
Newspaper Article (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3554) 3554
animals (2696) 2696
biotechnology & applied microbiology (2095) 2095
humans (1932) 1932
proteins (1772) 1772
microbiology (1286) 1286
recombinant proteins (1181) 1181
gene expression (1030) 1030
expression (1006) 1006
recombinant fusion proteins - genetics (1003) 1003
recombinant proteins - genetics (1000) 1000
analysis (990) 990
biotechnology (972) 972
molecular sequence data (932) 932
amino acid sequence (904) 904
recombinant (903) 903
mice (895) 895
escherichia-coli (888) 888
biochemistry & molecular biology (880) 880
recombinant fusion proteins - metabolism (879) 879
research (865) 865
immunology (857) 857
escherichia coli - genetics (811) 811
female (740) 740
recombinant proteins - metabolism (721) 721
escherichia coli (698) 698
vaccines (687) 687
cloning, molecular (678) 678
antibodies (672) 672
enzymes (638) 638
purification (618) 618
antigens (612) 612
health aspects (572) 572
protein (564) 564
base sequence (546) 546
cloning (546) 546
research article (546) 546
physiological aspects (539) 539
life sciences (537) 537
biochemical research methods (535) 535
genetic engineering (524) 524
gene (515) 515
escherichia coli - metabolism (508) 508
genetic aspects (508) 508
enzyme-linked immunosorbent assay (488) 488
recombinant proteins - biosynthesis (479) 479
recombinant proteins - immunology (479) 479
genes (471) 471
male (463) 463
immunization (447) 447
recombinant proteins - chemistry (436) 436
e coli (430) 430
vaccination (429) 429
peptides (426) 426
viruses (417) 417
veterinary sciences (416) 416
bacteria (411) 411
virology (409) 409
medicine (396) 396
infection (393) 393
recombinant proteins - isolation & purification (383) 383
identification (380) 380
recombinant fusion proteins - immunology (380) 380
protein binding (372) 372
multidisciplinary sciences (371) 371
cell biology (367) 367
vaccine (359) 359
bacterial proteins - genetics (355) 355
fusion protein (349) 349
recombinant fusion proteins - chemistry (347) 347
genetic vectors (343) 343
plant sciences (342) 342
cattle (341) 341
science (339) 339
mice, inbred balb c (332) 332
plasmids (330) 330
dna (329) 329
cell line (325) 325
infections (322) 322
medicine, research & experimental (322) 322
cells (313) 313
recombinant fusion proteins - biosynthesis (313) 313
recombinant fusion proteins - isolation & purification (299) 299
parasitology (296) 296
studies (295) 295
chemistry (293) 293
biology (292) 292
immune response (290) 290
recombinant protein (281) 281
infectious diseases (276) 276
article (275) 275
biochemistry, general (273) 273
plants (269) 269
methods (267) 267
immunogenicity (263) 263
usage (262) 262
biochemistry (254) 254
amino acids (251) 251
bacterial proteins - metabolism (249) 249
fermentation (247) 247
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (83) 83
UofT at Mississauga - Stacks (36) 36
UofT at Scarborough - Stacks (21) 21
UTL at Downsview - May be requested (19) 19
Engineering & Comp. Sci. - Stacks (18) 18
Earth Sciences (Noranda) - Stacks (9) 9
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
St. Michael's College (John M. Kelly) - 2nd Floor (8) 8
Robarts - Stacks (7) 7
St. Augustine's Seminary - Stacks (7) 7
Law (Bora Laskin) - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Online Resources - Online (3) 3
Gerstein Science - Searching (2) 2
Regis College - Stacks (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Earth Sciences (Noranda) - Missing (1) 1
OISE - Curriculum Resources (1) 1
OISE - Missing (1) 1
OISE - Stacks (1) 1
Physics - Missing (1) 1
Royal Ontario Museum - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UofT at Mississauga - Not Returned (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6388) 6388
Spanish (13) 13
Chinese (7) 7
German (5) 5
Japanese (5) 5
Portuguese (4) 4
French (3) 3
Czech (2) 2
Polish (2) 2
Danish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 03/2009, Volume 4, Issue 3, p. e4792
Gaucher disease is a progressive lysosomal storage disorder caused by the deficiency of glucocerebrosidase leading to the dysfunction in multiple organ... 
MULTIDISCIPLINARY SCIENCES | Recombinant Fusion Proteins - immunology | Recombinant Fusion Proteins - isolation & purification | Glucosylceramidase - genetics | Recombinant Fusion Proteins - economics | Recombinant Fusion Proteins - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Glucosylceramidase - adverse effects | Half-Life | Macaca fascicularis | Male | Neutralization Tests | Daucus carota - cytology | Young Adult | Clinical Trials, Phase III as Topic | Transfection | Adult | Female | Drug Evaluation, Preclinical | Gaucher Disease - drug therapy | Gaucher Disease - enzymology | Glucosylceramidase - isolation & purification | Glucosylceramidase - immunology | Cells, Cultured - enzymology | Glucosylceramidase - economics | Animals | Gaucher Disease - genetics | Glucosylceramidase - therapeutic use | Recombinant Fusion Proteins - pharmacokinetics | Antibody Formation | Infusions, Intravenous | Glucosylceramidase - pharmacokinetics | Viral antibodies | Enzymes | Biological products | Clinical trials | Primates | Antibodies | Hydrolases | Gene therapy | Drug approval | Cells | Cell culture | Intravenous administration | Disease | Science | Monkeys | Transgenic plants | Regulatory approval | Plant cells | Proteins | Toxicology | Trends | Safety | Drug dosages | Gaucher's disease | Recombinant | Immunoglobulins | Radioactive half-life | Pharmacology | FDA approval | Plants | Monkeys & apes | Studies | Hospitals | Immunogenicity | Glucosylceramidase | Laboratory animals | Pharmacokinetics
Journal Article
Journal Article
JAMA Ophthalmology, ISSN 2168-6165, 01/2016, Volume 134, Issue 1, pp. 95 - 99
Journal Article
British Journal of Ophthalmology, ISSN 0007-1161, 08/2015, Volume 99, Issue 8, pp. 1055 - 1059
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2018, Volume 13, Issue 5, p. e0197670
Background The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues.... 
EYE | VISUAL-ACUITY | INTRAVITREAL RANIBIZUMAB | CLINICAL-TRIAL | EFFICACY | MULTIDISCIPLINARY SCIENCES | QUALITY-OF-LIFE | MODEL | OUTCOMES | Drug Costs | Recombinant Fusion Proteins - economics | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Intravitreal Injections | Humans | Recombinant Fusion Proteins - therapeutic use | Drug Approval | Ranibizumab - therapeutic use | Off-Label Use - economics | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - economics | Macular Degeneration - drug therapy | Cost Savings | Angiogenesis Inhibitors - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - economics | Bevacizumab - economics | Recombinant Fusion Proteins - administration & dosage | Quality-Adjusted Life Years | Bevacizumab - administration & dosage | Drug Administration Schedule | Europe | Decision Support Techniques | Treatment Outcome | Visual Acuity | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Health Care Costs | Cost-Benefit Analysis | Ranibizumab - administration & dosage | Ranibizumab - economics | Macular degeneration | Drug therapy | Analysis | Medical care, Cost of | Drugs | Medical personnel | Medical services | Injection | Patients | Age related diseases | Doctors | Bevacizumab | Quality of life | Vision | Expenditures | Ophthalmology | Clinical medicine | Cost analysis | Vascular endothelial growth factor | Age | Overspending
Journal Article
Journal Article
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 01/2014, Volume 160, Issue 1, pp. 18 - 29
Background: Macular edema is the most common cause of vision loss among patients with diabetes. Objective: To determine the cost-effectiveness of different... 
MEDICINE, GENERAL & INTERNAL | VISUAL IMPAIRMENT | RANIBIZUMAB PLUS PROMPT | PHOTOCOAGULATION | RANDOMIZED-TRIAL | FOLLOW-UP | RETINOPATHY | INTRAVITREAL BEVACIZUMAB | UTILITY VALUES | TRIAMCINOLONE | DEFERRED LASER | Administration, Ophthalmic | Markov Chains | Recombinant Fusion Proteins - economics | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Vascular Endothelial Growth Factor A - economics | Male | Triamcinolone - economics | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Laser Therapy - economics | Bevacizumab | Diabetic Retinopathy - complications | Antibodies, Monoclonal, Humanized - economics | Anti-Inflammatory Agents - therapeutic use | Female | Anti-Inflammatory Agents - economics | Receptors, Vascular Endothelial Growth Factor - economics | Triamcinolone - therapeutic use | Quality-Adjusted Life Years | Antibodies, Monoclonal, Humanized - therapeutic use | Treatment Outcome | Combined Modality Therapy | Diabetic Retinopathy - therapy | Macular Edema - therapy | Visual Acuity | Disease Progression | Cost-Benefit Analysis | Macular Edema - complications | Complications and side effects | Care and treatment | Economic aspects | Eye diseases | Diabetes | Drug therapy | Cost benefit analysis | Laser therapy
Journal Article
Journal Article